Immunophotodynamics therapy: Current developments and future prospects

Drug Development Research

Volumn 42, Issue 3-4, 1997, Pages 182-197

  Miller, Gerald G ^a   Lown, J William ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Formulations; Immunotargeting; Phototherapy

Indexed keywords

ANTIBODY CONJUGATE; BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT;

CYTOTOXICITY; DRUG TARGETING; HUMAN; ILLUMINATION; IMMUNOTHERAPY; IN VITRO STUDY; LEUKEMIA CELL; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; SCAR FORMATION;

EID: 0031393981     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199711/12)42:3/4<182::AID-DDR10>3.0.CO;2-B     Document Type: Review

References (108)

1. Ahn ST, Monafo WW, Mustoe TA (1989): Topical silicone gel for the prevention and treatment of hypertorphic scar. Arch Surg 126:499-504.
2. 6. Cancer Res 55:1014-1019.
3. Amano T, Front GR Jr, Lin CW (1988): Intratumor injection as a more effective means of porphyrin administration for photodynamic therapy. J Urol 139:392-395.
4. Ames BN, McCann J, Yamasaki E (1975): Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 113:347-364.
5. Baas P, Oppelaar H, van der Valk MA, van Zanwijk N, Stewart FA (1994): Partial protection of photodynamic-induced skin reactions in mice by n-acetylcysteine: A preclinical study. Photochem Photobiol 59(4):448-454.
6. Bachor R, Flotte TJ, Scholz M, Dretler P, Hasan T (1992): Comparison of intravenous and intravesical administration of chloro-aluminium sulfonated phthalocyanine for photodynamic treatment in a rat bladder cancer model. J Urol 147:1404-1410.
7. Bachor R, Reich E, Miller K, Rück A, Hautmann R (1995): Photodynamic efficiency of liposome-administered tetramethyl hematoporphyrin in two human bladder cancer cell lines. Urol Res 23:151-156.
8. Baum RP, Noujaim AA, Nanci A, Moebus V, Hertel A, Niesen A, Donnerstag B, Sykes T, Boniface G, Hör G (1993): Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. Hybridoma 12:583-589.
9. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, Hör G (1994): Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 73:1121-1125.
10. Bhattacharya-Chatterjee M, Foon KA, Kohler H (1994): Idiotype antibody immunotherapy of cancer (Review). Cancer Immunol Immunother 38:75-82.
11. Bottiroli G, Croce AC, Balzarini P, Locatelli D, Baglioni P, Lo Nostro P, Monici M, Pratesi R (1997): Enzyme-assisted cell photosensitization: A proposal for an efficient approach to tumor therapy and diagnosis. The Rose Bengal fluorogenic substrate. Photochem Photobiol 66(3):374-383.
12. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 31:1035-1044.
13. Chen Q, Wilson BC, Shetty SD Patterson MS, Cerny JC, Hetzel FW (1997): Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res 147:86-91.
14. Cheong W-F, Prahl SA, Welch AJ (1990): A review of the optical properties of biological tissues. IEEE J Quant Electron 26:2166-2185.
15. Chopp M, Dereski MO, Madigan L, Jiang F, Logie B (1996): Sensitivity of 9L gliosarcomas to photodynamic therapy. Radiat Res 146:461-465.
16. Cortese DA, Kinsey JH (1984): Hematoporphyrin derivative phototherapy in the treatment of bronchogenic carcinoma. Chest 86:8-13.
17. Cosman B, Wolff M (1972): Correlation of keloid recurrence with completeness of local excision. A negative report. Plast Reconstr Surg 50:163-166.
18. Croce AC, Locatelli D, Monici M, Spano A, Pippia P, Bernabei P, Baglioni P, Bottiroli G (1997): Application of fluorogenic substrates to photodynamic therapy: Rose Bengal acetate. Lasers Surg Med Suppl 9:26.
19. Damato BE, Campbell AM, McGuire BH, Lee WR, Foulds WS (1986): Monoclonal antibodies to human primary uveal melanomas demonstrate tumor heterogeneity. Invest Ophtalmol Vis Sci 27:1362-1367.
20. Davis RK, Straight R, Dereszti Z (1990): Comparison of photosensitizers in saline and liposomes for tumor photodynamic therapy and skin phototoxicity. Laryngoscope 100:682-686.
21. Deckelbaum LI, Scott JJ, Stetz ML, O'Brien KM, Baker G (1990): Detection of atherosclerotic plaque by laser-induced plasma emission. Circulation 82(Suppl III):105.
22. Delaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas G, Dachowski L, Cole JW, Steinberg SM, Glatstein E (1993): Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 25:445-447.
23. Diwu Z (1995): Novel therapeutic and diagnostic applications of hypocrellins and hypericins (Review). Photochem Photobiol 61(6):529-539.
24. Diwu Z, Lown JW (1990): Hypocrellins and their use in photosensitization (Review). Photochem Photobiol 52(3):609-616.
25. Diwu Z, Lown JW (1992): A simple high-yielding approach to perylenequinone from the novel one-step double coupling reaction of 1,2-naphthoquinone. Tetrahedron 48(1):45-54.
26. Diwu Z, Lown JW (1993): Photosensitization with anticancer agents 15. Perylenequinonoid pigments as potential photodynamic therapeutic agents: Formation of semiquinone radicals and reactive oxygen species on illumination. J Photochem Photobiol B 18:131-143.
27. Duska LR, Hamblin MR, Bamberg MP, Hasan T (1997): Biodistribution of charged F(ab′)2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br J Cancer 75(6):837-844.
28. Eary JF Schroff RW, Abrams PG et al. (1989): Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J Nucl Med 30:25-32.
29. Elmets CA, Bowen KD (1986): Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. Cancer Res 46:1608-1611.
30. Estey EP, Brown K, Diwu Z, Liu J, Lown JW, Miller GG, Moore RB, Tulip I, McPhee MS (1996): Hypocrellins as photosensitizers for photodynamic therapy: A screening evaluation and pharmacokinetic study. Cancer Chemother Pharmacol 37:343-350.
31. Fisher WG, Partridge WP, Dees C, Wachter EA (1997): Simultaneous two-photon activation of type-I photodynamic therapy agents. Photochem Photobiol 66(2):141-155.
32. Fung PYS, Madej M, Koganty RR, Longenecker BM (1990): Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308-4314.
33. Goff BA, Bamberg MP, Hasan T (1991): Photoimmunotherapy of human ovarian cancer cells ex vivo. Cancer Res 51:4762-4767.
34. Goff BA, Blake J, Bamberg MP, Hasan T (1996): Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer 74:1194-1198.
35. Goldenberg DM (ed) (1990): Cancer Imaging With Radiolabeled Antibodies. Boston: Kluwer Academic Publishers.
36. Gomer CJ (1991): Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol 54:1093-1097.
37. Hamblin MR, Newman EL (1994): Photosensitizer targeting in photodynamic therapy. I. Conjugates of haematoporphyrin with albumin and transferrin. J Photochem Photobiol B 26:45-56.
38. Hamblin MR, Miller JL, Hasan T (1996): The effect of charge on the interaction of site-specific photosensitizer immunoconjugates with human ovarian cancer cells. Cancer Res 56:5205-5210.
39. Hasan T, Lin CW, Lin A (1989): Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates. Prog Clin Biol Res 288:471-477.
40. Henderson BW, Dougherty TJ (1992): How does photodynamic therapy work? Photochem Photobiol 55:145-157.
41. Hill JS, Kahl SB, Kaye AH, Stylli SS, Koo M-S, Gonzales MF, Vardaxis NJ, Johnson CI (1992): Selective tumor uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc Natl Acad Sci USA 89:1785-1789.
42. Hill JS, Kahl SB, Stylli SS, Nakamuru Y, Koo M-S, Kaye AH (1995): Selective tumor kill of cerebral glioma by photodynamic therapy using a boronated porphyrin photosensitizer. Proc Natl Acad Sci USA 92:12126-12130.
43. Himmelweit B (ed) (1957): The Collected Papers of Paul Ehrlich. Oxford, England: Pergammon Press.
44. Hu LK, Hasan T, Gragoudas S, Young LHY (1995): Photoimmunotherapy of human uveal melanoma cells. Exp Eye Res 61:385-391.
45. Jiang FN, Jiang S, Liu D, Richter A, Levy JG (1990): Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Meth 134:139-149.
46. Jiang FX, Liu DJ, Neyndorff H, Chester M, Jiang S, Levy JG (1991): Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J Natl Cancer Inst 83:1218-1225.
47. Jiang FN, Richter AM, Jain AK, Levy JG, Smits C (1993): Biodistribution of a benzoporphyrin derivative-monoclonal antibody conjugate in A549-tumor-bearing nude mice. Biotechnol Ther 41(1-2):43-61.
48. Jori G (1989): In vivo transport and pharmacokinetic behaviour of tumor photosensitizers. In: Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use. Chichester, UK: Wiley, pp 78-94.
49. Kahl SB, Koo M-S (1990): Synthesis of tetrakis-carborane-carboxylate esters of 2,4-bis-(alpha, beta-dihydroxyethyl) deuteroporphyrin. J Chem Soc Chem Commun 24:1769-1771.
50. Karlan BY, Amin W, Casper SE, Littlefield BA (1988): Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: Inhibition by glucocorticoids. Cancer Res 48:3502-3506.
51. Korbelik M (1996): Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 17:329-334.
52. Korbelik M, Krosl G (1996): Photosensitizer distribution and photosensitized damage of tumor tissues. In Hönigsman H, Jori G, Young AR (eds): The Fundamental Bases of Phototherapy. Milan: OEMF spa, pp 229-245.
53. Korbelik M, Naraparaju VR, N Yamamoto (1997): Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75(2):202-207.
54. Larrabee WF Jr, East CA, Jaffe HS (1990): Intralesional interferon-gamma treatment of keloids and hypertrphic scars. Arch Otol Head Neck Surg 116(10):1159-1162.
55. Lilge L, Dabrowski W, Holdsworth D, Blake J, Kato D, Wilson B, Hasan T (1994): Light delivery and dosimetry for photodynamic therapy in an ovarian-cancer mouse model. Proc Soc Photo-optical Instrumentation Engineers 2133:150-161.
56. Lipson RL, Baldes EJ, Olsen AM (1961): The use of a derivative of haemotoporphyrin in tumor detection. J Natl Cancer Inst 26:1-8.
57. MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T, Longenecker BM (1992): Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 11:292-305.
58. Madiyalakan R, Sykes TR, Dharampaul S, Sykes CJ, Baum RP, Hör G, Noujaim AA (1995): Antiidiotype induction therapy: Evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. Hybridoma 14(2):199-203.
59. Manske JM, Buchsbaum DJ, Azemove SM, Hanna DE, Vallera DA (1986): Antigenic modulation by anti-CD5 immunotoxins. J Immunol 136:4721-4728.
60. Matthay KK, Heath TD, Badger CC, Bernstein ID, Papahadjopoulos D (1986): Antibody-directed liposomes: Comparison of various ligands for association, endocytosis, and drug delivery. Cancer Res 46:4904-1910.
61. Mazière JC, Morlière P, Santus R (1990): New trends in photobiology (invited review). The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours. J Photochem Photobiol B 8:351-360.
62. McCaughan JS Jr (1987): Overview of experiences with photodynamic therapy for malignancy in 192 patients. Photochem Photobiol 46:903-909.
63. Mew D, Wat C-K, Towers GHN, Levy JG (1983): Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 130:1473-1477.
64. Mew D, Lum V, Wat C-K, Towers GHN, Sun CHC, Walter RJ, Wright W, Berns MW, Levy JG (1985): Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. Cancer Res 45:4380-4386.
65. Meyer M, Speight P, Bown SG (1991): A study of the effects of photodynamic therapy on the normal tissues of the rabbit jaw. Br J Cancer 64:1093-1097.
66. Miller GG, Brown K, Moore RB, Diwu ZJ, Liu J, Huang L, Lown JW, Begg DA, Chlumecky V, Tulip J, McPhee MS (1995): Uptake kinetics and intracellular localization of hypocrellin photosensitizers for photodynamic therapy: A confocal microscopy study. Photochem Photobiol 61(6):632-638.
67. Miller GG, Brown K, Ballangrud ÅM, Barajas O, Xiao Z, Tulip J, Lown JW, Leithoff JM, Allalunis-Turner MJ, Mehta RD, Moore RB (1997): Preclinical assessment of hypocrellin B and hypocrellin B derivatives as sensitizers for photodynamic therapy of cancer: Progress update. Photochem Photobiol 65(4):714-722.
68. Moan J, Peng Q, Evensen JF, Berg K, Western A, Rimington C (1987): Photosensitizing efficiencies, tumor and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol 46(5):713-721.
69. Molpus KL, Kato D, Hamblin MR, Lilge L, Bamberg M, Hasan T (1996): Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res 56:1075-1082.
70. Morgan CG, Yianni YP, Sandhu SS, Mitchell AC (1995): Liposome fusion and lipid exchange on ultraviolet irradiation of liposomes containing a photochromic phospholipid. Photochem Photobiol 62(1):24-29.
71. Morgan J, Gray AG, Huehns ER (1989): Specific targeting and toxicity to sulphonated aluminum phthalocyanine photosensitized liposomes directed to cells by monoclonal antibody in vitro. Br J Cancer 59:366-370.
72. Morgan J, Lottman H, Abbou CC, Chopin DK (1994): A comparison of direct and liposomal antibody conjugates of sulfonated aluminum phthalocyanines for selective photoimmunotherapy of human bladder carcinoma. Photochem Photobiol 60(5):486-196.
73. Mosley ST, Goldstein JL, Brown MS, Falck JR, Anderson RGW (1981): Targeted killing of cultured cells by receptor-dependent photosensitization. Proc Natl Acad Sci USA 78:5217-5221.
74. Nseyo UO, Whalen RK, Lunclahl SL (1993): Canine bladder response to red and green light whole bladder photodynamic therapy. Urology 41(4):392-396.
75. Oseroff AR, Ohuoha D, Hasan T, Bommer JC, Yarmush ML (1986): Antibody-targeted photolysis: Selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc Natl Acad Sci USA 83:8744-8748.
76. Pandurangi RS, Karra SR, Kuntz RR, Volkert WA (1996): Preservation of immunoreactivity in the photolabeling of the B72.3 human antibody. Photochem Photobiol 64(1):100-105.
77. Pogue BW, Hasan T (1997): A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat Res 147:551-559.
78. Pottier R, Kennedy JC (1990): New trends in photobiology (invited review). The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J Photochem Photobiol B 8:1-16.
79. Rassmussen-Taxdal DS, Ward GE, Figge FHI (1955): Fluorescence of human lymphatic and cancer tissue following high doses of intravenous hematoporphyrin. Cancer 8:78-81.
80. Ratcliffe SL, Matthews EK (1995): Modification of the photodynamic action of δ-aminolaevulinic acid (ALA) on rat pancreatoma cells by mitochondrial benzodiazepine receptor ligands. Br J Cancer 71:300-305.
81. Rebeiz N, Rebeiz CC, Arkins S, Kelley KW, Rebeiz CA (1992): Photodestruction of tumor cells by induction of endogenous accumulation of protoporphyrin IX: Enhancement by 1,10-phenanthroline. Photochem Photobiol 55(3):431-435.
82. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG (1993): Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol 57(6):1000-1006.
83. Ris H-B, Altermatt HJ, Steward CM, Schaffner T, Wang Q, Lim CK, Bonnett R, Althaus U (1993): Photodynamic therapy with m-tetrahydroxyphenylchlorin in vivo: Optimization of the therapeutic index. Int J Cancer 55:245-249.
84. Schmidt S (1993): Antibody-targeted photodynamic therapy. Hybridoma 12(5):539-541.
85. Schmidt S, Wagner U, Schultes B, Oehr P, Decleer W, Ertmer W, Lubaschowski H, Biersack HJ, Krebs B (1992): Photodynamic laser therapy with antibody-bound dyes. A new procedure in therapy of gynecologic malignancies (German language). Fortschr Med 110:298-301.
86. Schmidt-Erfurth U, Diddens H, Birngruber R, Hasan T (1997): Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer 75(1):54-61.
87. Schultes BC, Spaniol S, Schmidt S, Ertmer W, Biersack H-J, Krebs D (1994): Photodynamic lasertherapy with antibody-coupled phthalocyanine. Proc Soc Photo-optical Instrumentation Engineers 2078:148-157.
88. Sindelar WF, Delaney TF, Tochner Z, Thomas GF, Dachowski LJ, Smith PD, Friauf WS, Cole JW, Glatstein E (1991): Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms. Arch Surg 126:318-324.
89. Star W (1995): In vivo action spectra, absorption and fluorescence excitation spectra of photosensitizers for photodynamic therapy. J Photochem Photobiol B 28:101-102.
90. Steele JK, Liu D, Stammers AT, Deal H, Whitney S, Levy JG (1988): Suppressor deletion therapy: Selective elimination of T suppressor cells using a hematoporphyrin conjugated monoclonal antibody. In Rodwell JD (ed): Antibody-Mediated Delivery Systems. New York: Marcel Dekker, pp 157-189.
91. Stewart FA, Oussoren Y (1993): Functional and histological bladder damage in mice after photodynamic therapy: The influence of sensitiser dose and time of administration. Br J Cancer 68:673-677.
92. Svanberg K, Andersson T, Killander D, Wang I, Stenram U, Andersson-Engels S, Berg R, Johansson J, Svanberg S (1994): Photodynamic therapy of non-melanoma malignant tumours of the skin using topical δ-amino levulinic acid sensitization and laser irradiation. Br J Dermatol 130:743-751.
93. Thistlethewaite AJ, Leeper B, Moylar DJ III, Nerlinger RD (1985): pH distribution in human tumors. Int J Radiat Oncol Biol Phys 11:1647-1652.
94. Thorpe WP, Toner M, Exxell RM, Tompkins GG, Yarmush ML (1995): Photoinduced cell plasma membrane injury. Biophys J 68:2198-2206.
95. Tochner Z, Mitchell JB, Harrington FS, Smith P, Russo DT, Russo A (1985): Treatment of murine intraperitoneal ovarian ascitic tumor with hematoporphyrin derivative and laser light. Cancer Res 45:2983-2987.
96. Trail PA, Willner D, Hellström KE (1995): Site-directed delivery of anthracyclines for treatment of cancer. Drug Dev Res 34:196-209.
97. Tralau CJ, Barr H, Sandeman DR, Barton T, Lewin MR, Bown SG (1987): Aluminum sulfonated phthalocyanine distribution in rodent tumors of the colon, brain and pancreas. J Photochem Photobiol 46(5):777-781.
98. van der Veen N, van Leengoed HLLM, Star WM (1994): In vivo fluorescence kinetics and photodynamic therapy using 5-aminolaevulinic acid-induced porphyrin: Increased damage after multiple irradiations. Br J Cancer 70:867-872.
99. van Hillegersberg R, Berg JW, Kort WJ, Terpstra OT, Wilson JHP (1992): Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology 103:647-651.
100. van Hillegersberg R, Kort WJ, Wilson JHP (1994): Current status of photodynamic therapy in oncology (Review). Drugs 48(4):510-527.
101. van Leengoed HLLM, Cuomo V, Versteeg AAC, van der Veen B, Jori G, Star WM (1994): In vivo fluorescence and photodynamic activity of zinc phthalocyanine administered in liposomes. Br J Cancer 69(6):840-845.
102. Veenhuizen RB, Ruevekamp MC, Oppelaar H, Ransdorp B, van de Vijver M, Helmerhorst TJM, Kenemans P, Stewart FA (1997): Intraperitoneal photodynamic therapy: Comparison of red and green light distribution and toxicity. Photochem Photobiol 66(3):389-395.
103. Wike-Hooley JL, Haverman J, Reinhold HS (1984): The relevance of tumor pH to the treatment of malignant diseases. Radiother Oncol 2:343-366.
104. Wolfort SF, Reiken SR, Berthiaume F, Tompkins RG, Yarmush ML (1996): Control of hyperthrophic scar growth using antibody-targeted photolysis. J Surg Res 62:17-22.
105. Yamamoto N, Homma S, Sery TW, Donoso LA, Hoober KJ (1991): Photodynamic immunopotentiation: In vitro activation of macrophages by treatment of peritoneal cells with hematoporphyrin derivative and light. Eur J Cancer 27:467-171.
106. Yemul S, Berger C, Estabrook A, Edelson R, Bayley H (1985): The delivery of phototoxic drugs to selected cells. Ann NY Acad Sci 446:403-114.
107. Yemul S, Berger C, Estabrook A, Suarez S, Edelson R, Bayley H (1987): Selective killing of T lymphocytes by phototoxic liposomes. Proc Natl Acad Sci USA 84:246-250.
108. Yemul S, Berger C, Katz M, Estabrook A, Edelson R, Bayley H (1990): Phototoxic liposomes coupled to an antibody that alone cannot modulate its cell-surface antigen kill selected target cells. Cancer Immunol Immunother 30:317-322.